# SL Science Holding Limited share price today (SL Science Holding Limited, SLBT)

> SL Science Holding Limited's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. SLBT · Healthcare · Biotechnology · data as of 4 November 2026. Page: https://www.sectoralpha.in/us/stocks/slbt

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $1.11 (−89.3% in a year)
- Revenue (Jun 2025): $565 K (−7.5% on a year ago)
- Profit (Jun 2025), incl. one-off: −$801 K (one-off item, see below)
- Operating margin: −142.5% (−101.9 points on a year ago)

Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. ## What is the SL Science Holding Limited share price today? SL Science Holding Limited's share price was $1.11 at the close on 4 November 2026. That is 81.5% below its average price over the last 200 trading days. In the last 52 weeks it traded between $1 and $13, and at that close it was at the low of that range. Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 36 weeks running. Over the last 1 year the share price moved −89% while the S&P 500 moved +22%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 27 February 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does SL Science Holding Limited pay? SL Science Holding Limited pays no dividend. In the last 4 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is SL Science Holding Limited on? SL Science Holding Limited is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is SL Science Holding Limited profitable? SL Science Holding Limited posted a net loss of $801 K in the Jun 2025 quarter. That quarter includes a one-off gain bigger than its revenue, so the comparison with last year does not reflect normal business. The full FY24 year was a loss of $1.2 M. That loss is 141.8% of the quarter's revenue. For the full year, FY24 profit was −$1.2 M (−398.5% on the year before). Read this profit with care: at −$801 K it is bigger than the quarter's whole revenue of $565 K. No business earns more than it takes in from sales, so this is a one-off item (for example a debt settlement, a tax write-back or an asset sale), not money the business earned. The underlying business is running at a −142.5% operating margin. The jump on last year, and any P/E built on this profit, come from the one-off, not from a real turn in earnings. ## How much revenue does SL Science Holding Limited make, and is it growing? SL Science Holding Limited reported $565 K of revenue in the Jun 2025 quarter, −7.5% on the same quarter a year earlier. Over 1 years it has grown 282.7% a year on average. The last full year, FY24, came in at $3.4 M. Recent pace: the last four quarters grew −7.5% on average, against 282.7% a year over the longer run, so this year is growing slower than its own long-run rate. ## How much of every $100 of sales does SL Science Holding Limited keep? SL Science Holding Limited's operating margin was −142.5% in the Jun 2025 quarter, 101.9 percentage points lower than the same quarter a year ago. Across 2 years it has been between −35.6% and 11.0%. Why: the operating margin move is clear, but the cost details behind it are not in our data, so we show the move without guessing the reason. ## Is SL Science Holding Limited's profit turning into cash? SL Science Holding Limited's cash-flow history is too short to judge how much of its profit turns into cash. In FY24 it brought in $280 K of operating cash against −$1.2 M of profit. After $8.0 K of spending on assets, $272 K was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does SL Science Holding Limited's cash go? SL Science Holding Limited does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $191 K on assets over the last 2 years. Averaged over those years that is 2.8% of FY24 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $191 K over the last 2 years. In short: most of the cash goes on covering the loss, not on new assets; spending on assets is small next to it. ## What is SL Science Holding Limited's P/E ratio, and how does it compare with its own history? SL Science Holding Limited has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. Measured against sales instead, the market values SL Science Holding Limited at 188.2× its FY24 revenue of $3.4 M. The P/E comes back here once profit turns positive. ## Is the SL Science Holding Limited business getting better or worse? SL Science Holding Limited's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. Why it matters: with too little history, we say so rather than guess a direction. The latest quarter’s profit includes a one-off item bigger than the normal business, so the profit line is shown but does not count in this reading. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does SL Science Holding Limited earn on its capital? SL Science Holding Limited earned a ROE of −21% in FY24. Its return on capital used (ROIC) is left out: on sales this small it reads −139%, a number that says nothing useful about the business. It comes from a −35.4% net margin and 0.57× asset turnover (sales divided by assets). Why the return is what it is (FY24): a −35.4% net margin × 0.57× asset turnover × 1.04× leverage (assets divided by equity) ≈ −21.0% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed. ## Does SL Science Holding Limited have too much debt? SL Science Holding Limited's debt-to-equity is 0.06 at the latest reading: very little borrowing. A full history of its borrowings is not in our data. With so little borrowing, the returns on this page come from the business itself. We only have the latest reading, so no chart is drawn. ## What is the SL Science Holding Limited shareholding pattern? We have no ownership or short-position figures for SL Science Holding Limited, so this section says so rather than fill the gap. At normal trading volumes, closing those positions would take about 0.5 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. ## How far is SL Science Holding Limited from balance-sheet trouble? For SL Science Holding Limited, the Z-score is 48.75. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 48.75 is well clear of the danger zone, so the balance sheet is not the risk here. ## How does SL Science Holding Limited rank in its industry? There is no score against its industry: SL Science Holding Limited is not among the largest members shown in this industry comparison for Biotechnology. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is SL Science Holding Limited compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to SL Science Holding Limited in size? SL Science Holding Limited is the 132nd largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 5 November 2026). Just above it: Kura Oncology, Inc., Zevra Therapeutics, Inc. and Lexicon Pharmaceuticals, Inc. Just below it: DBV Technologies S.A., Crescent Biopharma, Inc. and Aclaris Therapeutics, Inc. ### Biotechnology companies close in size

1. [Kura Oncology, Inc.](https://www.sectoralpha.in/us/stocks/kura) $677 million
2. [Zevra Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/zvra) $665 million
3. [Lexicon Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/lxrx) $659 million
4. SL Science Holding Limited $633 million
5. [DBV Technologies S.A.](https://www.sectoralpha.in/us/stocks/dbvt) $622 million
6. [Crescent Biopharma, Inc.](https://www.sectoralpha.in/us/stocks/cbio) $592 million
7. [Aclaris Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/acrs) $570 million

[All 211 Biotechnology companies, largest first](https://www.sectoralpha.in/us/sectors/biotechnology#all-companies)

### Companies close in size in other industries

1. [Bitgo Holdings, Inc.](https://www.sectoralpha.in/us/stocks/btgo) $637 million · Capital Markets
2. [Matthews International Corporation](https://www.sectoralpha.in/us/stocks/matw) $634 million · Conglomerates
3. SL Science Holding Limited $633 million
4. [Sigma Lithium Corporation](https://www.sectoralpha.in/us/stocks/sgml) $633 million · Other Industrial Metals & Mining
5. [Sprout Social, Inc.](https://www.sectoralpha.in/us/stocks/spt) $630 million · Software - Application

## What else do people ask about SL Science Holding Limited? ### What were SL Science Holding Limited Limited's latest quarterly results? SL Science Holding Limited reported revenue of $565 K and a net loss of $801 K for the Jun 2025 quarter. Earnings per share were −$0.22. The operating margin was −142.5%, 101.9 percentage points lower than a year earlier (as of 4 November 2026). ### What is SL Science Holding Limited Limited's market cap? SL Science Holding Limited's market capitalisation is $633 M at a stock price of $1.11. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 4 November 2026). ### How is SL Science Holding Limited Limited performing? SL Science Holding Limited's latest readings are below. Over the past 13 weeks it has done worse than the S&P 500, for 36 weeks running. This describes what the data did, not a rating (as of 4 November 2026). ### Will SL Science Holding Limited Limited's stock price go up? This page does not forecast SL Science Holding Limited's stock price. What it shows instead: the stock price is $1.11. Nobody can reliably say which way a price will move, and this site does not try (as of 4 November 2026). ### Where is SL Science Holding Limited Limited in its business cycle? SL Science Holding Limited's FY24 operating margin was −35.6%, against a 2-year range of −35.6% to 11.0%: the low end of its own range, which is often where recoveries start. The latest quarter was −142.5%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 4 November 2026). ### What could break the SL Science Holding Limited Limited story? Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 4 November 2026). ### Is SL Science Holding Limited Limited a stock worth studying right now? What the numbers show: SL Science Holding Limited's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 4 November 2026). This is research, not advice. We’re not SEBI-registered.